ASTRAZEN — Astrazeneca Pharma India Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹218.13bn
- IN₹213.22bn
- IN₹12.96bn
Annual cashflow statement for Astrazeneca Pharma India, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 1,140 | 1,271 | 830 | 1,341 | 2,195 |
| Depreciation | |||||
| Non-Cash Items | -88.3 | -59.3 | -72.9 | -211 | -220 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -363 | -365 | 81 | -710 | -1,846 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 874 | 1,048 | 1,008 | 583 | 279 |
| Capital Expenditures | -142 | -77.1 | -96.2 | -85.2 | -108 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -1,566 | 1,807 | 144 | 266 | 325 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1,708 | 1,730 | 47.4 | 181 | 217 |
| Financing Cash Flow Items | -16.5 | -10.9 | -9.5 | -6.3 | -5.2 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -63.6 | -89.7 | -94.6 | -245 | -444 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -897 | 2,688 | 961 | 519 | 52.3 |